Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from GSK

Biotech Daily: Cancer Causing Impurities In Merck's Diabetic Drug, Vir Bio-GSK Shun FDA Submission Plans For COVID-19 Treatment, Aethlon's Monkeypox Trial

Here's a roundup of top developments in the biotech space over the last 24 hours:

Benzinga

Exclusive-Rotavirus childhood vaccine shortage hits four African countries

Supplies of a vaccine to prevent the deadly rotavirus infection in children have either run out in Kenya, Tanzania, Senegal and Cameroon or are close to doing so, officials close to the roll-out told Reuters, after disruptions at drugmaker GSK.

Reuters

Biotech Daily: Regulatory Setback For CorMedix, Mersana & GSK In Cancer Pact, BARDA Funding For Opioid Overdose Hopeful

Here's a roundup of top developments in the biotech space over the last 24 hours:

Benzinga

From analysis to the latest developments in health,
read the most diverse news in one place.

5 Value Stocks to Buy Ahead of the Fall Season

The stock market has witnessed a rough ride amid macroeconomic headwinds this year. Despite the GDP decline for two consecutive quarters, economists believe the economy is far from recession. Here are five fundamentally solid value stocks AstroNova (ALOT), Bristol-Myers Squibb (BMY), Bluegreen Vacations (BVH), GSK (GSK), and Honda Motor (HMC),…

StockNews.com

Recap Of Friday's Biotech Catalysts - End of The Day Summary

The U.S. Food and Drug Administration (FDA) has approved Arcutis Biotherapeutics’ (NASDAQ:ARQT) New Drug Application (NDA) for ZORYVE (roflumilast) cream 0.3% for the treatment of plaque psoriasis in patients 12 years of age or older. The company expects commercial launch of the product in Mid-August. Arcutis shares traded in a range of…

Benzinga

Recap of Wednesday's Biotech Catalysts - End of The Day Summary

IDEAYA Biosciences (NASDAQ:IDYA) has entered into a clinical trial collaboration and supply agreement with Amgen Inc. to evaluate the efficacy and safety of IDE397 with Amgen's AMG 193 in a Phase 1 clinical trial. IDEAYA shares traded in a range of $14.59 to $15.82 on a day volume of 130.58…

Benzinga

FTSE 100 Live: Fed rates rise, Lloyds and GSK lift 2022 guidance

The US Federal Reserve has increased benchmark borrowing costs by 0.75% for the second time in a row, in the latest sign of the stronger measures being taken by central banks to try and tame runaway inflation.

Evening Standard

Read news from The Economist, FT, and more,
with one subscription

‘Silent killer’ disease researchers to receive £4.4m drug trial funding

Experts will aim to develop new treatments for Chagas disease, which can kill victims without them knowing they were infected.

The Independent UK

Leading figures urge drugs firm to lower price of ‘game-changing’ HIV prevention drug

Signatories including Olly Alexander, Stephen Fry and Joseph Stiglitz issue a letter asking ViiV to make cabotegravir affordable to low- and middle-income countries

The Guardian - UK

RTE's Teresa Mannion was 'stopped in her tracks' after contracting shingles while studying for her Leaving Certificate

Exclusive: The RTE star was left in severe pain for three weeks when she was a teenager after contracting the illness.

Irish Mirror

Haleon’s debut suggests it may not be the jewel in GSK’s medicine cabinet

Consumer goods spin-off makes few waves in biggest European listing for more than a decade

The Guardian - UK

Benzinga Before The Bell: Amazon Wages Price War On Tesco, Biden's Campaign Promise To Free Cannabis Prisoners, H&M Exits Russia And Other Top Financial Stories Monday, July 18

Reuters GSK Completes Spin-Off Of Its Consumer Healthcare Business

Benzinga

City relief as GSK’s Haleon gets £31 billion float away

Panadol and Chapstick giant joins FTSE 100

Evening Standard

GSK spin-off Haleon begins trading in biggest European listing in a decade

Consumer health company ends first day on London Stock Exchange with £28.5bn market valuation

The Guardian - UK

Get all your
news in one place.

100’s of premium titles.
One news app.

Benzinga

Science Wednesday: Where To See Comet K2 As It Passes The Earth

Five years ago, astronomers were electrified to confirm the discovery of Comet C/2017 K2, more commonly known as Comet K2. At the time, it was believed to be one of the largest comets zooming across the universe, with a nucleus believed to be around 11 miles in diameter and a…

Reuters

Why world's first malaria shot won't reach millions of children who need it

After decades of work, the World Health Organization endorsed the first-ever malaria vaccine last year - a historic milestone that promised to drive back a disease that kills a child every minute.

Benzinga

The Daily Biotech Pulse: GSK To Supply 50M Flu Vaccine Doses To US, FDA Lifts Hold On Greenwich's Cancer Immunotherapy Trial, Connect Biopharma Sees CBP-201 Topline Data Sooner

Here's a roundup of top developments in the biotech space over the last 24 hours:

The Independent UK

This is how Nigerians are fighting an epidemic with highest number of child pneumonia deaths in the world

Nigerian photographer Yagazie Emezi travels across her home country to document the ongoing epidemic of child pneumonia

Get all your
news in one place.

100’s of premium titles.
One news app.

The Hindu

India’s patent law safeguards under fire

The new recommendation reduces the period within which patent applications can be challenged to six months

Benzinga

Ideaya Nominates Potential First-In-Class Pol Theta Helicase Inhibitor In Collaboration With GSK

Ideaya Biosciences Inc (NASDAQ:IDYA) has selected a potential first-in-class Pol Theta Helicase development candidate, a small molecule inhibitor of the helicase domain of DNA Polymerase Theta. Ideaya is collaborating with GSK plc (NYSE:GSK) on IND-enabling studies to support the evaluation of the Pol Theta Helicase candidate in combination with niraparib, GSK's PARP inhibitor, in tumors with…

Benzinga

GSK Shares Encouraging Data From Chronic Hepatitis B Candidate

GSK plc (NYSE:GSK) announced promising interim results from the B-Clear phase 2b trial of bepirovirsen in people with chronic hepatitis B (CHB). The data showed that bepirovirsen reduced hepatitis B surface antigen (HBsAg) levels and hepatitis B virus (HBV) DNA after 24 weeks of treatment. In the group of 227 patients on standard…

Benzinga

Sanofi-GSK's Beta-Containing COVID-19 Vaccine Shows Efficacy Against Omicron

Sanofi SA (NASDAQ:SNY) and GSK plc (NYSE:GSK) have announced positive data from their vaccine trial of adjuvanted bivalent D614 and Beta (B.1.351) vaccine candidate. "Sanofi-GSK's vaccine is the first candidate to demonstrate efficacy in a placebo-controlled trial in an environment of high Omicron variant circulation," Sanofi said in a statement. The bivalent vaccine targets the…

Insider UK

Kynos Therapeutics appoints chief finance officer

She will combine her current role as COO at NodThera while supporting the Edinburgh medtech firm

Birmingham Post

Pharmaceutical giant GSK opens new £90m North East manufacturing site

The company says the opening of Q Block will allow the Barnard Castle site to strengthen its global role

Benzinga

Analyzing GSK's Short Interest

GSK's (NYSE:GSK) short percent of float has fallen 17.24% since its last report. The company recently reported that it has 6.02 million shares sold short, which is 0.24% of all regular shares that are available for trading.

1 … 10 11 12 13

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.